Climb Bio, Inc. vs Chemomab Therapeutics Ltd. — Valuation Comparison 2026
Access all valuation models for CLYM vs CMMB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →CLYM scores higher with a 4.1/10 quality rating vs CMMB's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Climb Bio, Inc. (CLYM) and Chemomab Therapeutics Ltd. (CMMB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
CLYM currently trades at $11.34 with a QOC of 4.1/10, while CMMB trades at $2.07 with a QOC of 1.9/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).